硼替佐米
蛋白酶体
蛋白酶体抑制剂
华登氏巨球蛋白血症
巨球蛋白血症
癌症研究
医学
蛋白激酶B
内科学
药理学
化学
生物
磷酸化
多发性骨髓瘤
生物化学
淋巴瘤
作者
Aldo M. Roccaro,Antonio Sacco,Monette Aujay,Hai T. Ngo,Abdel Kareem Azab,Feda Azab,Phong Quang,Patricia Maiso,Judith Runnels,Kenneth C. Anderson,Susan D. Demo,Irene M. Ghobrial
出处
期刊:Blood
[Elsevier BV]
日期:2010-01-29
卷期号:115 (20): 4051-4060
被引量:78
标识
DOI:10.1182/blood-2009-09-243402
摘要
Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenström macroglobulinemia (WM), where bortezomib has been successfully tested in clinical trials. Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-target effects. Selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive proteasome 20S (c20S) and immunoproteasome 20S (i20S) represents a sufficient and successful strategy to induce antineoplastic effect in hematologic tumors. We therefore studied ONX0912, a novel selective, irreversible inhibitor of the CT-L activity of i20S and c20S. Primary WM cells express higher level of i20S compared with c20S, and that ONX0912 inhibited the CT-L activity of both i20S and c20S, leading to induction of toxicity in primary WM cells, as well as of apoptosis through c-Jun N-terminal kinase activation, nuclear factor kappaB (NF-kappaB) inhibition, caspase cleavage, and initiation of the unfolded protein response. Importantly, ONX0912 exerted toxicity in WM cells, by reducing bone marrow (BM)-derived interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1) secretion, thus inhibiting BM-induced p-Akt and phosphorylated extracellular signal-related kinase (p-ERK) activation in WM cells. These findings suggest that targeting i20S and c20S CT-L activity by ONX0912 represents a valid antitumor therapy in WM.
科研通智能强力驱动
Strongly Powered by AbleSci AI